NCT04182633View on ClinicalTrials.gov

MTT for Children With ASD Who Have Gastrointestinal Disorders

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

February 28, 2025

Study Completion Date

December 30, 2025

Conditions
Autism Spectrum DisorderGastro-Intestinal DisorderConstipationDiarrhea
Interventions
COMBINATION_PRODUCT

vancomycin, Miralax, intestinal microbiota

vancomycin for 14 days, then Miralax for 1 day, then intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)

COMBINATION_PRODUCT

placebo vancomycin, Miralax, placebo intestinal microbiota

placebo vancomycin for 14 days, then Miralax for 1 day, then placebo intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)

Trial Locations (1)

85287

Arizona State University, Tempe

All Listed Sponsors
collaborator

University of Minnesota

OTHER

lead

Arizona State University

OTHER

NCT04182633 - MTT for Children With ASD Who Have Gastrointestinal Disorders | Biotech Hunter | Biotech Hunter